Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
申请人:——
公开号:US20020010175A1
公开(公告)日:2002-01-24
The present invention relates to the use of diazepinoindoles of the formula (I):
1
in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical,
for the treatment of chronic obstructive pulmonary disease.
Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
申请人:WARNER-LAMBERT COMPANY
公开号:EP1161950A1
公开(公告)日:2001-12-12
The present invention relates to the use of diazepinoindoles of the formula (I):
in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical,
for the treatment of chronic obstructive pulmonary disease.
本发明涉及式(I)的重氮吲哚的用途:
其中 A 是芳基或含氮杂芳基,B 是羟基或氨基、
用于治疗慢性阻塞性肺病。
Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
申请人:WARNER-LAMBERT COMPANY
公开号:EP1161949A1
公开(公告)日:2001-12-12
The present invention relates to the use of diazepinoindoles of the formula (I):
in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical,
for the treatment of chronic obstructive pulmonary disease.
本发明涉及式(I)的重氮吲哚的用途:
其中 A 是芳基或含氮杂芳基,B 是羟基或氨基、
用于治疗慢性阻塞性肺病。
Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
申请人:Nycomed GmbH
公开号:EP1849468A2
公开(公告)日:2007-10-31
The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.
本发明涉及联合使用 PDE4 或 PDE3/4 抑制剂和组胺受体拮抗剂治疗呼吸系统疾病。
DIAZEPINO-INDOLES INHIBITEURS DE PHOSPHODIESTERASES 4